Ligand Pharmaceuticals (LGNDZ) Other Gross PP&E Adjustments (2016 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with $3.0 million as the latest value for Q4 2025.
- Quarterly Other Gross PP&E Adjustments fell 74.22% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, down 74.22% year-over-year, with the annual reading at $3.0 million for FY2025, 74.22% down from the prior year.
- Other Gross PP&E Adjustments hit $3.0 million in Q4 2025 for Ligand Pharmaceuticals, up from -$7.6 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $24.0 million in Q4 2021 to a low of -$24.7 million in Q2 2022.
- Historically, Other Gross PP&E Adjustments has averaged -$3.3 million across 5 years, with a median of -$6.4 million in 2021.
- Biggest YoY gain for Other Gross PP&E Adjustments was 759.92% in 2021; the steepest drop was 293.42% in 2021.
- Year by year, Other Gross PP&E Adjustments stood at $24.0 million in 2021, then dropped by 25.12% to $17.9 million in 2022, then dropped by 23.06% to $13.8 million in 2023, then fell by 15.72% to $11.6 million in 2024, then crashed by 74.22% to $3.0 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for LGNDZ at $3.0 million in Q4 2025, -$7.6 million in Q3 2025, and -$8.0 million in Q2 2025.